Long-Acting Treatments: Shaping the Future of Retinal Disease Management

Retinal diseases like wet age-related macular degeneration (AMD) and geographic atrophy (GA) affect millions globally. In the U.S. alone, 1.8 million people are impacted by wet AMD. The SOL-1 trial results for AXPAXLI, a long-acting treatment, highlight its effectiveness in reducing vision loss in wet AMD patients, with 74.1% maintaining visual acuity compared to 55.8% with aflibercept. Let's delve into how these treatments are transforming patient care and what they mean for the future of retinal disease management.

Understanding the Distinction: Wet AMD vs. GA

Wet AMD and GA, though related to AMD, require distinct treatment approaches. Wet AMD involves abnormal blood vessel growth, leading to rapid vision loss, while GA is characterized by the gradual degeneration of retinal cells. Treatments like AXPAXLI focus on wet AMD by targeting vascular endothelial growth factor (VEGF), whereas GA treatments like Syfovre and Izervay address the complement pathway.

The Rise of Long-Acting Wet AMD Treatments

AXPAXLI and Its Role

AXPAXLI has emerged as a significant player in the management of wet AMD. The SOL-1 trial demonstrated its potential to maintain visual acuity over 36 weeks, reducing the need for frequent injections. This sustained-release mechanism offers patients fewer clinic visits and a more manageable treatment regimen.

Comparing Treatment Options

Beyond AXPAXLI, other long-acting treatments such as OTX-TKI and faricimab are gaining attention. These options provide extended dosing intervals, which can improve adherence and reduce the burden on both patients and healthcare providers. Understanding the differences between these treatments can help practitioners tailor solutions to individual patient needs.

The Impact on Patient Care

Enhancing Quality of Life

Reducing the frequency of injections can significantly improve a patient's quality of life. It minimizes the discomfort and anxiety associated with regular procedures and reduces no-show rates, which are often a challenge in retinal practices. This shift towards long-acting treatments can lead to better adherence and outcomes.

Managing Expectations

While the data from trials like SOL-1 is promising, real-world scenarios often require supplemental injections. Patients must be informed about the potential need for additional treatments to set realistic expectations and ensure continued engagement with their care plan.

Questions to Ask Your Retina Specialist

When considering long-acting treatments, it's crucial to have informed discussions with your retina specialist. Here are some tailored questions:

• How does AXPAXLI fit into my current wet AMD treatment plan?
• What are the potential side effects, and how do they compare to other treatments?
• What should I expect in terms of treatment frequency and lifestyle adjustments?

Conclusion

Long-acting treatments are redefining retinal disease management, offering patients new hope for maintaining vision. By understanding the distinct needs of wet AMD and GA, and engaging in open dialogue with healthcare providers, patients can make informed decisions about their treatment options. Explore these advancements with your retina specialist to determine the best path forward for your eye health.